Human VEGF165 Antibody
R&D Systems, part of Bio-Techne | Catalog # AB-293-NA
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse, Rat, Primate - Macaca mulatta (Rhesus Macaque)
Applications
Validated:
Immunohistochemistry, Neutralization, Western Blot
Cited:
Bioassay, Complex Application, ELISA Development, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGF165
Ala27-Arg191
Accession # AAV38412
Ala27-Arg191
Accession # AAV38412
Specificity
Detects human VEGF165 and human VEGF121 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human VEGF165 Antibody
VEGF165in Human Breast Cancer Tissue.
VEGF165was detected in immersion fixed frozen sections of human breast cancer tissue using 5 µg/mL Human VEGF165Polyclonal Antibody (Catalog # AB-293-NA) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.Cell Proliferation Induced by VEGF165and Neutralization by Human VEGF Antibody.
Recombinant Human VEGF165(Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF165(10 ng/mL) is neutralized (green line) by increasing concentrations of Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA). The ND50 is typically 0.600-7.20 µg/mL.VEGF in Human Breast Cancer Tissue.
VEGF was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.Applications for Human VEGF165 Antibody
Application
Recommended Usage
Immunohistochemistry
5-15 µg/mL
Sample: Immersion fixed frozen or paraffin-embedded sections of human breast cancer tissue
Sample: Immersion fixed frozen or paraffin-embedded sections of human breast cancer tissue
Western Blot
1 µg/mL
Sample: Recombinant Human VEGF165 (Catalog # 293-VE)
Sample: Recombinant Human VEGF165 (Catalog # 293-VE)
Neutralization
Measured by its ability to neutralize VEGF165-induced proliferation in HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci USA 87:1323. The Neutralization Dose (ND50) is typically 0.600-7.20 µg/mL in the presence of 10 ng/mL Recombinant Human VEGF165.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Reconstitution
Reconstitute at 1 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF
Long Name
Vascular Endothelial Growth Factor
Alternate Names
MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF
Entrez Gene IDs
Gene Symbol
VEGFA
UniProt
Additional VEGF Products
Product Documents for Human VEGF165 Antibody
Product Specific Notices for Human VEGF165 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...